Monday, March 3, 2008

Biotech Firm to Provide Alternatives to Vaccines Using Tissue From Abortions

A biotech firm has announced it will offer ethical alternatives to some of the vaccines that currently rely on the use of fetal tissue from abortions. The Seattle-based AVM Biotechnology says it will produce ethical alternatives in the fields of biotechnology, pharmaceuticals, and vaccine development.

The news gives hope to pro-life people who have been reluctant to use some vaccines because their development came as a result of the destruction of unborn children.

“We will be working to bring commercially available, morally acceptable, vaccines to the US market and to use existing technology to produce new morally certified vaccines," says Dr. Theresa Deisher, the research and development director for AVM.

"Revenues from the vaccine business will also further the research, development and commercialization of morally certified therapeutics in other areas of medicine as well," she added.


It's about time!